The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.

The trial was terminated early, on the recommendation of the Data Monitoring Committee, due to a sustained and highly significant reduction in the risk of the primary composite end point (CV death or HF hospitalisation) and in CV mortality in the sacubitril/valsartan group compared with the enalapril group.

also in 132,142 other papers